Business · 08/08/2024Updated: 10/17/2026 · 1 min read
Flamingo Pharmaceuticals Ltd. Faces FDA Proposal to Withdraw Approval of Two ANDAs
Summary
The FDA is proposing to withdraw approval of two Abbreviated New Drug Applications (ANDAs) held by Flamingo Pharmaceuticals Ltd. due to repeated failure to file required annual reports, and is offering the company an opportunity to request a hearing on the proposal.